| Autor: |
de Araújo EA; Postgraduate Program in Cardiology, Universidade Federal de São Paulo (UNIFESP), São Paulo 04024-000, SP, Brazil., Tallo FS; Discipline of Urgency and Emergency Care, Universidade Federal de São Paulo (UNIFESP), São Paulo 04024-000, SP, Brazil., Oliveira ASF; Postgraduate Program in Interdisciplinary Surgical Science, Universidade Federal de São Paulo (UNIFESP), São Paulo 04024-002, SP, Brazil., Toghlobi GSSE; Department of Medicine, Universidade Santo Amaro (UNISA), São Paulo 04829-300, SP, Brazil., Arantes RA; Department of Medicine, Universidade Santo Amaro (UNISA), São Paulo 04829-300, SP, Brazil., Balsimelli R; Department of Medicine, Universidade Santo Amaro (UNISA), São Paulo 04829-300, SP, Brazil., Kehrwald-Balsimelli B; Department of Medicine, Universidade Santo Amaro (UNISA), São Paulo 04829-300, SP, Brazil., de Almeida Viana BL; Department of Medicine, Universidade Santo Amaro (UNISA), São Paulo 04829-300, SP, Brazil., Matuda FS; Department of Medicine, Universidade Nove de Julho (UNINOVE), São Paulo 01504-001, SP, Brazil., Nicolau LAD; Research Center on Biodiversity and Biotechnology, Universidade Federal do Delta do Parnaíba (UFDPar), Parnaíba 64202-020, PI, Brazil., Medeiros JVR; Research Center on Biodiversity and Biotechnology, Universidade Federal do Delta do Parnaíba (UFDPar), Parnaíba 64202-020, PI, Brazil., Caixeta A; Postgraduate Program in Cardiology, Universidade Federal de São Paulo (UNIFESP), São Paulo 04024-000, SP, Brazil., Taha MO; Postgraduate Program in Interdisciplinary Surgical Science, Universidade Federal de São Paulo (UNIFESP), São Paulo 04024-002, SP, Brazil., Gomes WJ; Discipline of Cardiovascular Surgery, Universidade Federal de São Paulo (UNIFESP), São Paulo 04024-000, SP, Brazil., Caricati-Neto A; Department of Pharmacology, Universidade Federal de São Paulo (UNIFESP), São Paulo 04023-062, SP, Brazil., Menezes-Rodrigues FS; Postgraduate Program in Cardiology, Universidade Federal de São Paulo (UNIFESP), São Paulo 04024-000, SP, Brazil.; Postgraduate Program in Interdisciplinary Surgical Science, Universidade Federal de São Paulo (UNIFESP), São Paulo 04024-002, SP, Brazil. |
| Abstrakt: |
Defined as systemic hypotension caused by intense vasodilation due to the loss of systemic vascular resistance, vasoplegic syndrome (VS) is associated with elevated morbidity and mortality in humans. Although vasopressors such as norepinephrine and vasopressin are the first-choice drugs for VS treatment, several other drugs such as methylene blue (MB) can be used as adjuvant therapy including rescue therapy. To develop new pharmacological strategies to reduce the risk of VS, we investigated the effects of treatments with MB (2 mg/kg/IV), omeprazole (OME, 10 mg/kg/IV), and their combination in an animal model of cardiac ischemia-reperfusion (CIR). The ventricular arrhythmia (VA), atrioventricular block (AVB), and lethality (LET) incidence rates caused by CIR (evaluated via ECG) and serum levels of the cardiac lesion biomarkers creatine kinase-MB (CK-MB) and troponin I (TnI) in adult rats pretreated with saline solution 0.9% and submitted to CIR (SS + CIR group) were compared to those pretreated with MB (MB + CIR group), OME (OME + CIR group), or the MB + OME combination (MB + OME + CIR group). The AVB and LET incidence rates in the MB + CIR (100%), OME + CIR (100%), and MB + OME + CIR (100%) groups were significantly higher compared to the SS + CIR group (60%). The serum level of CK-MB in these groups were also significantly higher compared to the SS + CIR group, demonstrating that the treatments before CIR with MB, OME, and MB + OME produced similar effects in relation to cardiac function and the occurrence of lesions. These results demonstrate that the treatment of animals subjected to the CIR protocol with OME produced the same effects promoted by the treatment with MB, which may suggest the possibility of using OME alone or in combination with MB in medical clinics in treatment of VS. |
